Optimal dosing scheme of neuromuscular blocking agent

A compasiron of rocuronium dosing based on total body weight and skeletal muscle mass

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0004829

Enrollment

280

Registered

2020-03-13

Start date

2020-03-16

Completion date

Unknown

Last updated

2020-03-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : - Participants in control group will receive rocuronium determined by total body weight, on the other hand, participants in experimental group will receive rocuronium determined by skeletal mus

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients, aged 18 to 75 years, American Society of Anesthesiologists Physical Status I or II, undergoing surgery under general anesthesia for 1 hour or more

Exclusion criteria

Exclusion criteria: 1) Anticipated difficult airway management 2) Patients with past history of neuromuscular disease 3) Severe hepatic or renal impairment 4) drug allergy to rocuroium 5) Patients undergoing major surgery with high possibility of massive bleeding or transfusion 6) Patients with implatable metal product such as cardiac pacamaker or ICD 7) Pregnancy

Design outcomes

Primary

Measure	Time frame
onset time of rocuronium	—

Secondary

Measure	Time frame
Duration of rocuronium	—

Countries

Korea, Republic of

Contacts

Public ContactA Ram Doo

Chonbuk National University

Outcome results